ProfileGDS5678 / 1424030_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 54% 52% 54% 54% 54% 52% 57% 66% 54% 52% 54% 54% 54% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3616653
GSM967853U87-EV human glioblastoma xenograft - Control 23.3453454
GSM967854U87-EV human glioblastoma xenograft - Control 33.2582652
GSM967855U87-EV human glioblastoma xenograft - Control 43.2845254
GSM967856U87-EV human glioblastoma xenograft - Control 53.2805454
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4489954
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.349252
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4337657
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.955666
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3343954
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2425652
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3081154
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3323154
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3349154